<?xml version='1.0' encoding='utf-8'?>
<document id="19372982"><sentence text="Differences in the pharmacokinetics of protease inhibitors between healthy volunteers and HIV-infected persons." /><sentence text="Pharmacokinetic and drug-drug interaction studies are conducted in both healthy volunteers and the target population (HIV-infected patients), but there is little discussion of the potential for differences in drug disposition between the two groups" /><sentence text=" It is important to recognize that the pharmacokinetics of drugs may be altered in HIV-infected persons as compared with healthy individuals" /><sentence text=" The aim of this review is to highlight some of the important differences in drug handling between healthy volunteers and HIV-infected individuals, focusing on protease inhibitors" /><sentence text="" /><sentence text="Studies aimed at characterizing disparities in pharmacokinetics between healthy volunteers and HIV patients are lacking" /><sentence text=" Data suggest that concentrations of some protease inhibitors are lower in HIV patients than in HIV-negative volunteers (atazanavir and tipranavir), but generally comparisons are made across studies and study centres, and so multiple variables, such as differences in food and study design, can influence findings"><entity charOffset="121-131" id="DDI-PubMed.19372982.s7.e0" text="atazanavir" /><entity charOffset="136-146" id="DDI-PubMed.19372982.s7.e1" text="tipranavir" /><pair ddi="false" e1="DDI-PubMed.19372982.s7.e0" e2="DDI-PubMed.19372982.s7.e0" /><pair ddi="false" e1="DDI-PubMed.19372982.s7.e0" e2="DDI-PubMed.19372982.s7.e1" /></sentence><sentence text=" We have conducted an 'in-house' analysis, comparing atazanavir, lopinavir and saquinavir between HIV-infected patients and healthy volunteers enrolled in the same study centre with similar study designs"><entity charOffset="53-63" id="DDI-PubMed.19372982.s8.e0" text="atazanavir" /><entity charOffset="65-74" id="DDI-PubMed.19372982.s8.e1" text="lopinavir" /><entity charOffset="79-89" id="DDI-PubMed.19372982.s8.e2" text="saquinavir" /><pair ddi="false" e1="DDI-PubMed.19372982.s8.e0" e2="DDI-PubMed.19372982.s8.e0" /><pair ddi="false" e1="DDI-PubMed.19372982.s8.e0" e2="DDI-PubMed.19372982.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19372982.s8.e0" e2="DDI-PubMed.19372982.s8.e2" /><pair ddi="false" e1="DDI-PubMed.19372982.s8.e1" e2="DDI-PubMed.19372982.s8.e1" /><pair ddi="false" e1="DDI-PubMed.19372982.s8.e1" e2="DDI-PubMed.19372982.s8.e2" /></sentence><sentence text="" /><sentence text="For atazanavir the current data are quite convincing that concentrations are lower in HIV-infected patients than in healthy individuals, but for others it is not so clear"><entity charOffset="4-14" id="DDI-PubMed.19372982.s10.e0" text="atazanavir" /></sentence><sentence text=" The 'in-house' analyses for atazanavir, lopinavir and saquinavir attempted to address some of the difficulties with cross-study comparisons, but it should be noted that subject numbers were small"><entity charOffset="29-39" id="DDI-PubMed.19372982.s11.e0" text="atazanavir" /><entity charOffset="41-50" id="DDI-PubMed.19372982.s11.e1" text="lopinavir" /><entity charOffset="55-65" id="DDI-PubMed.19372982.s11.e2" text="saquinavir" /><pair ddi="false" e1="DDI-PubMed.19372982.s11.e0" e2="DDI-PubMed.19372982.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19372982.s11.e0" e2="DDI-PubMed.19372982.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19372982.s11.e0" e2="DDI-PubMed.19372982.s11.e2" /><pair ddi="false" e1="DDI-PubMed.19372982.s11.e1" e2="DDI-PubMed.19372982.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19372982.s11.e1" e2="DDI-PubMed.19372982.s11.e2" /></sentence><sentence text=" Physiological changes resulting from HIV disease can influence drug pharmacokinetics and the underlying mechanisms remain to be elucidated" /><sentence text="" /></document>